Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 11CNS 2Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Glioblastoma 28Glioma 20Brain Neoplasms 18Astrocytoma 13Neuroblastoma 12Lung Neoplasms 11Breast Neoplasms 10Medulloblastoma 9Central Nervous System Neoplasms 9Osteosarcoma 7Carcinoma, Non-Small-Cell Lung 7Wilms Tumor 6Lymphoma, Non-Hodgkin 6Hepatoblastoma 6Ependymoma 6Rhabdoid Tumor 5Neuroectodermal Tumors, Primitive, Peripheral 5Meningioma 5Meningeal Carcinomatosis 5Melanoma 5Histiocytosis, Langerhans-Cell 5Gliosarcoma 5Sarcoma 4Rhabdomyosarcoma 4Prostatic Neoplasms 4Pheochromocytoma 4Paraganglioma 4Neoplasm Metastasis 4Ganglioneuroblastoma 4Thyroid Neoplasms 3

Interventions

Magnetic Resonance Spectroscopy 4Nivolumab 3Gemcitabine 3Fluorodeoxyglucose F18 3olutasidenib 2olaparib 2durvalumab 2Specimen Handling 2FAPI-46 2Cisplatin 2ulixertinib 1pembrolizumab 1ivosidenib 1entrectinib 1enasidenib 1cobimetinib 1alectinib 1Topotecan 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1Molecular Diagnostic Techniques 1Metformin 1Ipilimumab 1Immunotherapy 1Folfox protocol 1Fluoresceins 1Fluorescein 1Drug Therapy 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Specimen Handling × CNS × Clear all
NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
798 enrolled
CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT03212274 2026-02-19

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

National Cancer Institute (NCI)

Phase 2 Active not recruiting
89 enrolled
CNSGastrointestinal

Glioblastoma, Glioma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡